Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
SYIEY Stock Summary
Top 10 Correlated ETFs
SYIEY
In the News
European Dividend Gems: Symrise AG
Symrise is one of the top players in the highly concentrated aroma molecules, flavours, and fragrances market. Ingredients from this company are used in products we use on a daily basis, resulting in steadily increasing sales and strong margins.
Symrise AG (SYIEF) Q4 2022 Earnings Call Transcript
Symrise AG (OTCPK:SYIEF) Q4 2022 Earnings Conference Call March 8, 2023 7:00 AM ET Company Participants Tobias Erfurth - Head, IR Heinz-Jurgen Bertram - CEO Stephanie Cossmann - Human Resources and Legal Jean-Yves Parisot - Executive Board member for Taste, Nutrition and Health Jorn Andreas - Scent and Care segment Olaf Klinger - CFO Conference Call Participants Matthew Yates - Bank of America Charles Eden - UBS Celine Pannuti - JP Morgan Isha Sharma - Stifel Oliver Schwarz - Warburg Andrew Benson - Citi Operator Welcome to the virtual Analyst Conference of Symrise. For your information, this call will be recorded.
All You Need to Know About Symrise AG Unsponsored ADR (SYIEY) Rating Upgrade to Strong Buy
Symrise AG Unsponsored ADR (SYIEY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Are Beauty Stocks Really Recession-Proof, or Even Recession-Resistant?
The 25-year history tells an interesting tale.
Symrise AG (SYIEF) CEO Dr. Heinz-Jürgen Bertram on Q4 2021 Results - Earnings Call Transcript
Symrise AG (SYIEF) CEO Dr. Heinz-Jürgen Bertram on Q4 2021 Results - Earnings Call Transcript
Symrise AG (SYIEF) CEO Heinz-Jürgen Bertram on Q2 2021 Results - Earnings Call Transcript
Symrise AG (SYIEF) CEO Heinz-Jürgen Bertram on Q2 2021 Results - Earnings Call Transcript
Symrise AG (SYIEF) CEO Heinz-Jürgen Bertram on 2020 Financial Results - Earnings Call Transcript
Symrise AG (SYIEF) CEO Heinz-Jürgen Bertram on 2020 Financial Results - Earnings Call Transcript
Burcon NutraScience: Compelling Pure-Play On Large And Expanding Plant-Protein Megatrend
Burcon NutraScience: Compelling Pure-Play On Large And Expanding Plant-Protein Megatrend
SYIEY Financial details
SYIEY Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 6.32 | 6.5 | 7 | 8.26 | 34 | |
Net income per share | 0.54 | 0.57 | 0.69 | 0.5 | 2.44 | |
Operating cash flow per share | 1.01 | 1.17 | 0.95 | 0.64 | 4.72 | |
Free cash flow per share | 0.69 | 0.91 | 0.64 | 0.2 | 2.79 | |
Cash per share | 0.85 | 1.37 | 0.85 | 0.56 | 2.81 | |
Book value per share | 4.46 | 4.25 | 5.83 | 6.35 | 25.98 | |
Tangible book value per share | -0.07 | 0.31 | 1.41 | 1.27 | 6.54 | |
Share holders equity per share | 4.46 | 4.25 | 5.83 | 6.35 | 25.98 | |
Interest debt per share | 3.92 | 3.93 | 3.37 | 4.66 | 17.82 | |
Market cap | 12.53B | 14.74B | 17.89B | 14.18B | 3.48B | |
Enterprise value | 14.14B | 16.09B | 19.24B | 16.41B | 5.63B | |
P/E ratio | 43.04 | 48.04 | 47.72 | 50.62 | 10.22 | |
Price to sales ratio | 3.68 | 4.19 | 4.68 | 3.07 | 0.73 | |
POCF ratio | 22.91 | 23.19 | 34.3 | 39.36 | 5.28 | |
PFCF ratio | 33.65 | 29.99 | 51.5 | 128.93 | 8.94 | |
P/B Ratio | 5.2 | 6.4 | 5.61 | 3.99 | 0.96 | |
PTB ratio | 5.2 | 6.4 | 5.61 | 3.99 | 0.96 | |
EV to sales | 4.15 | 4.57 | 5.03 | 3.55 | 1.19 | |
Enterprise value over EBITDA | 20.31 | 21.86 | 23.16 | 19.1 | 7.08 | |
EV to operating cash flow | 25.87 | 25.31 | 36.88 | 45.56 | 8.54 | |
EV to free cash flow | 37.99 | 32.73 | 55.37 | 149.24 | 14.46 | |
Earnings yield | 0.02 | 0.02 | 0.02 | 0.02 | 0.1 | |
Free cash flow yield | 0.03 | 0.03 | 0.02 | 0.01 | 0.11 | |
Debt to equity | 0.86 | 0.9 | 0.56 | 0.72 | 0.66 | |
Debt to assets | 0.35 | 0.35 | 0.27 | 0.33 | 0.3 | |
Net debt to EBITDA | 2.32 | 1.83 | 1.62 | 2.6 | 2.7 | |
Current ratio | 1.83 | 3.5 | 2.04 | 2.76 | 2.88 | |
Interest coverage | 9.03 | 8.43 | 14.38 | 8.55 | 5.14 | |
Income quality | 1.79 | 2.02 | 1.35 | 1.24 | 1.94 | |
Dividend Yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.04 | |
Payout ratio | 0.42 | 0.42 | 0.35 | 0.51 | 0.43 | |
Sales general and administrative to revenue | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | |
Research and developement to revenue | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | |
Intangibles to total assets | 0.42 | 0.37 | 0.37 | 0.37 | 0.35 | |
Capex to operating cash flow | -0.32 | -0.23 | -0.33 | -0.69 | -0.41 | |
Capex to revenue | -0.05 | -0.04 | -0.05 | -0.05 | -0.06 | |
Capex to depreciation | -0.77 | -0.57 | -0.68 | -0.86 | -0.93 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0.01 | -0.13 | |
Graham number | 7.36 | 7.36 | 9.49 | 8.46 | 37.73 | |
ROIC | 0.07 | 0.08 | 0.08 | 0.05 | 0.06 | |
Return on tangible assets | 0.08 | 0.08 | 0.09 | 0.06 | 0.06 | |
Graham Net | -3.87 | -3.59 | -3.28 | -4.39 | -18.31 | |
Working capital | 953.8M | 1.64B | 1.19B | 1.71B | 1.76B | |
Tangible asset value | -36.25M | 167.6M | 770.34M | 710.43M | 913.79M | |
Net current asset value | -1.4B | -1.28B | -1.06B | -1.49B | -1.64B | |
Invested capital | 0.86 | 0.9 | 0.56 | 0.72 | 0.66 | |
Average receivables | 646.15M | 643.44M | 733.01M | 918.83M | 999.8M | |
Average payables | 324.15M | 333.34M | 373.48M | 471.2M | 509.46M | |
Average inventory | 867.06M | 876.06M | 925.42M | 1.16B | 1.29B | |
Days sales outstanding | 71.78 | 63.94 | 81.03 | 78.11 | 77.66 | |
Days payables outstanding | 59.47 | 57.27 | 64.2 | 66.28 | 58.8 | |
Days of inventory on hand | 159.04 | 147.87 | 153.65 | 166.15 | 150.9 | |
Receivables turnover | 5.09 | 5.71 | 4.5 | 4.67 | 4.7 | |
Payables turnover | 6.14 | 6.37 | 5.69 | 5.51 | 6.21 | |
Inventory turnover | 2.29 | 2.47 | 2.38 | 2.2 | 2.42 | |
ROE | 0.12 | 0.13 | 0.12 | 0.08 | 0.09 | |
Capex per share | -0.32 | -0.27 | -0.32 | -0.45 | -1.93 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 8.39 | 16.87 | 8.62 | 17.27 | 16.57 | |
Net income per share | 0.18 | 0.37 | 0.67 | 1.34 | 1.09 | |
Operating cash flow per share | 1.1 | 2.01 | 0.51 | 0.81 | 3.91 | |
Free cash flow per share | 1.17 | 2 | 0.13 | 0.05 | 2.74 | |
Cash per share | 2.24 | 2.25 | 2.56 | 2.56 | 2.81 | |
Book value per share | 25.28 | 25.41 | 25.12 | 25.15 | 25.98 | |
Tangible book value per share | 5.47 | 5.08 | 5.32 | 5.33 | 6.54 | |
Share holders equity per share | 25.28 | 25.41 | 25.12 | 25.15 | 25.98 | |
Interest debt per share | 16.84 | 18.59 | 16.83 | 20.36 | 17.52 | |
Market cap | 3.48B | 3.54B | 3.49B | 3.38B | 3.48B | |
Enterprise value | 3.16B | 5.78B | 3.13B | 5.81B | 5.63B | |
P/E ratio | 33.94 | 17.3 | 9.29 | 4.5 | 5.69 | |
Price to sales ratio | 2.95 | 1.5 | 2.89 | 1.4 | 1.5 | |
POCF ratio | 22.56 | 12.64 | 48.5 | 29.7 | 6.38 | |
PFCF ratio | 21.2 | 12.66 | 188.42 | 486.66 | 9.1 | |
P/B Ratio | 0.98 | 1 | 0.99 | 0.96 | 0.96 | |
PTB ratio | 0.98 | 1 | 0.99 | 0.96 | 0.96 | |
EV to sales | 2.68 | 2.45 | 2.59 | 2.41 | 2.43 | |
Enterprise value over EBITDA | 14.22 | 15.69 | 14.24 | 14.32 | 15.57 | |
EV to operating cash flow | 20.52 | 20.6 | 43.51 | 51.12 | 10.31 | |
EV to free cash flow | 19.28 | 20.64 | 169.05 | 837.69 | 14.72 | |
Earnings yield | 0.01 | 0.01 | 0.03 | 0.06 | 0.04 | |
Free cash flow yield | 0.05 | 0.08 | 0.01 | 0 | 0.11 | |
Debt to equity | 0.67 | 0.72 | 0.67 | 0.79 | 0.66 | |
Debt to assets | 0.3 | 0.33 | 0.3 | 0.35 | 0.3 | |
Net debt to EBITDA | -1.42 | 6.06 | -1.63 | 6 | 5.95 | |
Current ratio | 2.76 | 2.76 | 2.59 | 2.59 | 2.88 | |
Interest coverage | 0 | 4.28 | 0 | 5.01 | 3.74 | |
Income quality | 6.02 | 5.48 | 0.77 | 0.61 | 3.57 | |
Dividend Yield | 0 | 0 | 0.02 | 0.04 | 0 | |
Payout ratio | 0 | 0 | 0.78 | 0.78 | 0 | |
Sales general and administrative to revenue | 0.05 | 0.03 | 0.06 | 0.03 | 0 | |
Research and developement to revenue | 0.06 | 0.06 | 0.05 | 0.05 | 0.06 | |
Intangibles to total assets | 0.37 | 0.37 | 0.36 | 0.36 | 0.35 | |
Capex to operating cash flow | 0.06 | 0 | -0.74 | -0.94 | -0.3 | |
Capex to revenue | 0.01 | 0 | -0.04 | -0.04 | -0.07 | |
Capex to depreciation | 0.11 | 0 | -0.74 | -0.74 | -1.1 | |
Stock based compensation to revenue | 0 | -0.14 | 0 | 0 | -0.04 | |
Graham number | 10.18 | 14.47 | 19.46 | 27.55 | 25.29 | |
ROIC | 0.01 | 0.02 | 0.02 | 0.03 | 0.03 | |
Return on tangible assets | 0.01 | 0.01 | 0.02 | 0.04 | 0.03 | |
Graham Net | -18.16 | -17.55 | -18.33 | -18.11 | -18.31 | |
Working capital | 1.71B | 1.71B | 1.74B | 1.74B | 1.76B | |
Tangible asset value | 768.72M | 710.43M | 744.69M | 744.69M | 913.79M | |
Net current asset value | -1.49B | -1.49B | -1.46B | -1.46B | -1.64B | |
Invested capital | 0.67 | 0.72 | 0.67 | 0.79 | 0.66 | |
Average receivables | 428.02M | 922.2M | 971.18M | 976.73M | 0 | |
Average payables | 516.27M | 529.61M | 476.2M | 422.8M | 0 | |
Average inventory | 1.27B | 1.33B | 1.33B | 1.33B | 0 | |
Days sales outstanding | 65.34 | 37.72 | 71.14 | 37.27 | 39.29 | |
Days payables outstanding | 62.43 | 31.22 | 49.59 | 24.79 | 29.3 | |
Days of inventory on hand | 156.49 | 78.25 | 155.67 | 77.84 | 75.21 | |
Receivables turnover | 1.38 | 2.39 | 1.27 | 2.42 | 2.29 | |
Payables turnover | 1.44 | 2.88 | 1.82 | 3.63 | 3.07 | |
Inventory turnover | 0.58 | 1.15 | 0.58 | 1.16 | 1.2 | |
ROE | 0.01 | 0.01 | 0.03 | 0.05 | 0.04 | |
Capex per share | 0.07 | 0 | -0.38 | -0.76 | -1.17 |
SYIEY Frequently Asked Questions
What is Symrise AG stock symbol ?
Symrise AG is a DE stock and trading under the symbol SYIEY
What is Symrise AG stock quote today ?
Symrise AG stock price is $29.7 today.
Is Symrise AG stock public?
Yes, Symrise AG is a publicly traded company.